Asset Details
Do you wish to reserve the book?
Incidence and predictors of synchronous liver metastases in patients with gastrointestinal stromal tumors (GISTs)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Incidence and predictors of synchronous liver metastases in patients with gastrointestinal stromal tumors (GISTs)
Do you wish to request the book?
Incidence and predictors of synchronous liver metastases in patients with gastrointestinal stromal tumors (GISTs)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Incidence and predictors of synchronous liver metastases in patients with gastrointestinal stromal tumors (GISTs)
2018
Overview
The liver is the most common metastatic site in patients with gastrointestinal stromal tumors (GISTs). The purpose of this study is to identify the incidence and predictive factors associated with synchronous liver metastases among patients with GISTs.
A retrospective review of the Surveillance Epidemiology and End Results (SEER) database was performed.
Overall, 2757 patients were identified, of which 276 (10%) had synchronous liver metastases. The two-year survival of patients with synchronous liver metastases was 31.9% overall and 37.1% after undergoing surgery with curative intent. Primary tumor size >5 cm (5–10 cm: OR 2.97, 95% CI: 1.03–8.55, p = 0.044, >10 cm: OR 5.59, 95% CI: 1.95–16.07, p = 0.001), presence of nodal metastases (OR 4.09, 95% CI: 2.01–8.33, p < 0.001) and mitotic count >5/50 HPF (OR 1.58, 95% CI: 1.01–2.47, p = 0.044) were associated with the presence of liver metastases.
One out of ten patients with GISTs presents with hepatic metastases. Primary tumor size >5 cm, presence of nodal metastases and mitotic count >5/50 HPF are associated with a higher risk of synchronous hepatic metastases.
•10% of patients with GISTs present with synchronous liver metastases.•Two-year survival of these patients is 31.9% overall and 37.1% after undergoing surgery.•Primary tumor location is a predictor of disease-specific survival in patients with synchronous liver metastases.•Tumor size >5 cm, presence of nodal metastases and mitotic count >5 /50 HPF are predictors of synchronous liver metastases.
